Demeclocycline seems to exert its action on the collecting duct of the nephron. At that site it is thought to interfere with elaboration of the intracellular second messenger of antidiuretic hormone, cyclic AMP-hence the nephrogenic diabetes insipidus which has been observed with the use of this drug.1 2 However, it is unlikely that antidiuretic hormone is involved in the pathogenesis of benign intracranial hypertension. As we concluded in our report, the underlying defect in benign intracranial hypertension seems to result in either accumulation of cerebrospinal fluid or intracellular overhydration of brain tissue. This occurs without any apparent disturbance of whole-body water homoeostasis.
Perhaps these disparate effects of tetracycline and its congeners result from an aberration of function of the cell membrane, firstly in the collecting duct of the nephron and secondly in the choroid plexus or "blood brain barrier." A recent hypothesis3 suggests that the arachnoid villi may be affected in benign intracranial hypertension so as to produce a large increase in the resistance to cerebrospinal fluid outflow, leading to a new steady-state cerebrospinal fluid pressure.
We believe that study of the effects of tetracycline on cell membranes may be rewarded by greater understanding of the pathogenesis of benign intracranial hypertension and indeed of cerebrospinal fluid dynamics. ABC of blood pressure reduction SIR,-In the recent series "ABC of blood pressure reduction" Dr Liam Bannan and others mention withdrawal phenomena after cessation of antihypertensive therapy only in relation to clonidine, about which they state (18 October, p 1055): "Sudden withdrawal of the drug is associated with rebound hypertension, which may be dangerously severe. If patients miss taking their tablets rebound rises in blood pressure may occur often. For this reason this drug has little place in modern treatment of hypertension." These statements raise several points for discussion.
Although definitive data are lacking, there is no clear evidence that withdrawal phenomena are more common or dangerous after cessation of clonidine therapy than with other drugs of its type-for example, methyldopa or even beta-blockers, a class of agents recommended as initial therapy.' Early reports of rebound and overshoot hypertension associated with sudden withdrawal of clonidine are characterised by the fact that clonidine was only one of several drugs used in the regimens. A reported case2 of late hypertension after clonidine withdrawal was later reviewed3 and claimed to reflect progression of the underlying disease rather than an effect of stopping clonidine.
Prospective studies have failed convincingly to demonstrate overshoot hypertension, though a phenomenon of sympathetic overactivity has been frequently described.4 For ethical and
